The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Diabetic Neuropathy Drugs Market Research Report 2024
Synopsis
Diabetic neuropathies are nerve damaging disorders associated with diabetes mellitus. These conditions are thought to result from a diabetic microvascular injury involving small blood vessels that supply nerves (vasa nervorum) in addition to macrovascular conditions that can accumulate in diabetic neuropathy.
The global Diabetic Neuropathy Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Diabetic Neuropathy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetic Neuropathy Drugs.
Report Scope
The Diabetic Neuropathy Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diabetic Neuropathy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diabetic Neuropathy Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis
Johnson & Johnson
Eli Lilly
GlaxoSmithKline
Boehringer Ingelheim
Teva Pharmaceutical
Daiichi Sankyo
Astellas Pharma
Segment by Type
Calcium Channel Alpha-2 Delta Ligand
SNRIs and TCAs
Others
Segment by Application
Hospitals
Drug Stores
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diabetic Neuropathy Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Diabetic neuropathies are nerve damaging disorders associated with diabetes mellitus. These conditions are thought to result from a diabetic microvascular injury involving small blood vessels that supply nerves (vasa nervorum) in addition to macrovascular conditions that can accumulate in diabetic neuropathy.
The global Diabetic Neuropathy Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Diabetic Neuropathy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetic Neuropathy Drugs.
Report Scope
The Diabetic Neuropathy Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diabetic Neuropathy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diabetic Neuropathy Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis
Johnson & Johnson
Eli Lilly
GlaxoSmithKline
Boehringer Ingelheim
Teva Pharmaceutical
Daiichi Sankyo
Astellas Pharma
Segment by Type
Calcium Channel Alpha-2 Delta Ligand
SNRIs and TCAs
Others
Segment by Application
Hospitals
Drug Stores
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diabetic Neuropathy Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Neuropathy Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Calcium Channel Alpha-2 Delta Ligand
1.2.3 SNRIs and TCAs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Diabetic Neuropathy Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Drug Stores
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Neuropathy Drugs Market Perspective (2019-2030)
2.2 Diabetic Neuropathy Drugs Growth Trends by Region
2.2.1 Global Diabetic Neuropathy Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Diabetic Neuropathy Drugs Historic Market Size by Region (2019-2024)
2.2.3 Diabetic Neuropathy Drugs Forecasted Market Size by Region (2025-2030)
2.3 Diabetic Neuropathy Drugs Market Dynamics
2.3.1 Diabetic Neuropathy Drugs Industry Trends
2.3.2 Diabetic Neuropathy Drugs Market Drivers
2.3.3 Diabetic Neuropathy Drugs Market Challenges
2.3.4 Diabetic Neuropathy Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Neuropathy Drugs Players by Revenue
3.1.1 Global Top Diabetic Neuropathy Drugs Players by Revenue (2019-2024)
3.1.2 Global Diabetic Neuropathy Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Diabetic Neuropathy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Diabetic Neuropathy Drugs Revenue
3.4 Global Diabetic Neuropathy Drugs Market Concentration Ratio
3.4.1 Global Diabetic Neuropathy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Neuropathy Drugs Revenue in 2023
3.5 Diabetic Neuropathy Drugs Key Players Head office and Area Served
3.6 Key Players Diabetic Neuropathy Drugs Product Solution and Service
3.7 Date of Enter into Diabetic Neuropathy Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetic Neuropathy Drugs Breakdown Data by Type
4.1 Global Diabetic Neuropathy Drugs Historic Market Size by Type (2019-2024)
4.2 Global Diabetic Neuropathy Drugs Forecasted Market Size by Type (2025-2030)
5 Diabetic Neuropathy Drugs Breakdown Data by Application
5.1 Global Diabetic Neuropathy Drugs Historic Market Size by Application (2019-2024)
5.2 Global Diabetic Neuropathy Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Diabetic Neuropathy Drugs Market Size (2019-2030)
6.2 North America Diabetic Neuropathy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Diabetic Neuropathy Drugs Market Size by Country (2019-2024)
6.4 North America Diabetic Neuropathy Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Diabetic Neuropathy Drugs Market Size (2019-2030)
7.2 Europe Diabetic Neuropathy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Diabetic Neuropathy Drugs Market Size by Country (2019-2024)
7.4 Europe Diabetic Neuropathy Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Neuropathy Drugs Market Size (2019-2030)
8.2 Asia-Pacific Diabetic Neuropathy Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Diabetic Neuropathy Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Diabetic Neuropathy Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Diabetic Neuropathy Drugs Market Size (2019-2030)
9.2 Latin America Diabetic Neuropathy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Diabetic Neuropathy Drugs Market Size by Country (2019-2024)
9.4 Latin America Diabetic Neuropathy Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Neuropathy Drugs Market Size (2019-2030)
10.2 Middle East & Africa Diabetic Neuropathy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Diabetic Neuropathy Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Diabetic Neuropathy Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Diabetic Neuropathy Drugs Introduction
11.1.4 Pfizer Revenue in Diabetic Neuropathy Drugs Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Diabetic Neuropathy Drugs Introduction
11.2.4 Novartis Revenue in Diabetic Neuropathy Drugs Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Diabetic Neuropathy Drugs Introduction
11.3.4 Johnson & Johnson Revenue in Diabetic Neuropathy Drugs Business (2019-2024)
11.3.5 Johnson & Johnson Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Detail
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Diabetic Neuropathy Drugs Introduction
11.4.4 Eli Lilly Revenue in Diabetic Neuropathy Drugs Business (2019-2024)
11.4.5 Eli Lilly Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Diabetic Neuropathy Drugs Introduction
11.5.4 GlaxoSmithKline Revenue in Diabetic Neuropathy Drugs Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Detail
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Diabetic Neuropathy Drugs Introduction
11.6.4 Boehringer Ingelheim Revenue in Diabetic Neuropathy Drugs Business (2019-2024)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Company Detail
11.7.2 Teva Pharmaceutical Business Overview
11.7.3 Teva Pharmaceutical Diabetic Neuropathy Drugs Introduction
11.7.4 Teva Pharmaceutical Revenue in Diabetic Neuropathy Drugs Business (2019-2024)
11.7.5 Teva Pharmaceutical Recent Development
11.8 Daiichi Sankyo
11.8.1 Daiichi Sankyo Company Detail
11.8.2 Daiichi Sankyo Business Overview
11.8.3 Daiichi Sankyo Diabetic Neuropathy Drugs Introduction
11.8.4 Daiichi Sankyo Revenue in Diabetic Neuropathy Drugs Business (2019-2024)
11.8.5 Daiichi Sankyo Recent Development
11.9 Astellas Pharma
11.9.1 Astellas Pharma Company Detail
11.9.2 Astellas Pharma Business Overview
11.9.3 Astellas Pharma Diabetic Neuropathy Drugs Introduction
11.9.4 Astellas Pharma Revenue in Diabetic Neuropathy Drugs Business (2019-2024)
11.9.5 Astellas Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Diabetic Neuropathy Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Calcium Channel Alpha-2 Delta Ligand
Table 3. Key Players of SNRIs and TCAs
Table 4. Key Players of Others
Table 5. Global Diabetic Neuropathy Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Diabetic Neuropathy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Diabetic Neuropathy Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Diabetic Neuropathy Drugs Market Share by Region (2019-2024)
Table 9. Global Diabetic Neuropathy Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Diabetic Neuropathy Drugs Market Share by Region (2025-2030)
Table 11. Diabetic Neuropathy Drugs Market Trends
Table 12. Diabetic Neuropathy Drugs Market Drivers
Table 13. Diabetic Neuropathy Drugs Market Challenges
Table 14. Diabetic Neuropathy Drugs Market Restraints
Table 15. Global Diabetic Neuropathy Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Diabetic Neuropathy Drugs Market Share by Players (2019-2024)
Table 17. Global Top Diabetic Neuropathy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetic Neuropathy Drugs as of 2023)
Table 18. Ranking of Global Top Diabetic Neuropathy Drugs Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Diabetic Neuropathy Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Diabetic Neuropathy Drugs Product Solution and Service
Table 22. Date of Enter into Diabetic Neuropathy Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Diabetic Neuropathy Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Diabetic Neuropathy Drugs Revenue Market Share by Type (2019-2024)
Table 26. Global Diabetic Neuropathy Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Diabetic Neuropathy Drugs Revenue Market Share by Type (2025-2030)
Table 28. Global Diabetic Neuropathy Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Diabetic Neuropathy Drugs Revenue Market Share by Application (2019-2024)
Table 30. Global Diabetic Neuropathy Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Diabetic Neuropathy Drugs Revenue Market Share by Application (2025-2030)
Table 32. North America Diabetic Neuropathy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Diabetic Neuropathy Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Diabetic Neuropathy Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Diabetic Neuropathy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Diabetic Neuropathy Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Diabetic Neuropathy Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Diabetic Neuropathy Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Diabetic Neuropathy Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Diabetic Neuropathy Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Diabetic Neuropathy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Diabetic Neuropathy Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Diabetic Neuropathy Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Diabetic Neuropathy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Diabetic Neuropathy Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Diabetic Neuropathy Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 47. Pfizer Company Detail
Table 48. Pfizer Business Overview
Table 49. Pfizer Diabetic Neuropathy Drugs Product
Table 50. Pfizer Revenue in Diabetic Neuropathy Drugs Business (2019-2024) & (US$ Million)
Table 51. Pfizer Recent Development
Table 52. Novartis Company Detail
Table 53. Novartis Business Overview
Table 54. Novartis Diabetic Neuropathy Drugs Product
Table 55. Novartis Revenue in Diabetic Neuropathy Drugs Business (2019-2024) & (US$ Million)
Table 56. Novartis Recent Development
Table 57. Johnson & Johnson Company Detail
Table 58. Johnson & Johnson Business Overview
Table 59. Johnson & Johnson Diabetic Neuropathy Drugs Product
Table 60. Johnson & Johnson Revenue in Diabetic Neuropathy Drugs Business (2019-2024) & (US$ Million)
Table 61. Johnson & Johnson Recent Development
Table 62. Eli Lilly Company Detail
Table 63. Eli Lilly Business Overview
Table 64. Eli Lilly Diabetic Neuropathy Drugs Product
Table 65. Eli Lilly Revenue in Diabetic Neuropathy Drugs Business (2019-2024) & (US$ Million)
Table 66. Eli Lilly Recent Development
Table 67. GlaxoSmithKline Company Detail
Table 68. GlaxoSmithKline Business Overview
Table 69. GlaxoSmithKline Diabetic Neuropathy Drugs Product
Table 70. GlaxoSmithKline Revenue in Diabetic Neuropathy Drugs Business (2019-2024) & (US$ Million)
Table 71. GlaxoSmithKline Recent Development
Table 72. Boehringer Ingelheim Company Detail
Table 73. Boehringer Ingelheim Business Overview
Table 74. Boehringer Ingelheim Diabetic Neuropathy Drugs Product
Table 75. Boehringer Ingelheim Revenue in Diabetic Neuropathy Drugs Business (2019-2024) & (US$ Million)
Table 76. Boehringer Ingelheim Recent Development
Table 77. Teva Pharmaceutical Company Detail
Table 78. Teva Pharmaceutical Business Overview
Table 79. Teva Pharmaceutical Diabetic Neuropathy Drugs Product
Table 80. Teva Pharmaceutical Revenue in Diabetic Neuropathy Drugs Business (2019-2024) & (US$ Million)
Table 81. Teva Pharmaceutical Recent Development
Table 82. Daiichi Sankyo Company Detail
Table 83. Daiichi Sankyo Business Overview
Table 84. Daiichi Sankyo Diabetic Neuropathy Drugs Product
Table 85. Daiichi Sankyo Revenue in Diabetic Neuropathy Drugs Business (2019-2024) & (US$ Million)
Table 86. Daiichi Sankyo Recent Development
Table 87. Astellas Pharma Company Detail
Table 88. Astellas Pharma Business Overview
Table 89. Astellas Pharma Diabetic Neuropathy Drugs Product
Table 90. Astellas Pharma Revenue in Diabetic Neuropathy Drugs Business (2019-2024) & (US$ Million)
Table 91. Astellas Pharma Recent Development
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Diabetic Neuropathy Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Diabetic Neuropathy Drugs Market Share by Type: 2023 VS 2030
Figure 3. Calcium Channel Alpha-2 Delta Ligand Features
Figure 4. SNRIs and TCAs Features
Figure 5. Others Features
Figure 6. Global Diabetic Neuropathy Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Diabetic Neuropathy Drugs Market Share by Application: 2023 VS 2030
Figure 8. Hospitals Case Studies
Figure 9. Drug Stores Case Studies
Figure 10. Others Case Studies
Figure 11. Diabetic Neuropathy Drugs Report Years Considered
Figure 12. Global Diabetic Neuropathy Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Diabetic Neuropathy Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Diabetic Neuropathy Drugs Market Share by Region: 2023 VS 2030
Figure 15. Global Diabetic Neuropathy Drugs Market Share by Players in 2023
Figure 16. Global Top Diabetic Neuropathy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetic Neuropathy Drugs as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Diabetic Neuropathy Drugs Revenue in 2023
Figure 18. North America Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Diabetic Neuropathy Drugs Market Share by Country (2019-2030)
Figure 20. United States Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Diabetic Neuropathy Drugs Market Share by Country (2019-2030)
Figure 24. Germany Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Diabetic Neuropathy Drugs Market Share by Region (2019-2030)
Figure 32. China Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Diabetic Neuropathy Drugs Market Share by Country (2019-2030)
Figure 40. Mexico Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Diabetic Neuropathy Drugs Market Share by Country (2019-2030)
Figure 44. Turkey Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Diabetic Neuropathy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Pfizer Revenue Growth Rate in Diabetic Neuropathy Drugs Business (2019-2024)
Figure 47. Novartis Revenue Growth Rate in Diabetic Neuropathy Drugs Business (2019-2024)
Figure 48. Johnson & Johnson Revenue Growth Rate in Diabetic Neuropathy Drugs Business (2019-2024)
Figure 49. Eli Lilly Revenue Growth Rate in Diabetic Neuropathy Drugs Business (2019-2024)
Figure 50. GlaxoSmithKline Revenue Growth Rate in Diabetic Neuropathy Drugs Business (2019-2024)
Figure 51. Boehringer Ingelheim Revenue Growth Rate in Diabetic Neuropathy Drugs Business (2019-2024)
Figure 52. Teva Pharmaceutical Revenue Growth Rate in Diabetic Neuropathy Drugs Business (2019-2024)
Figure 53. Daiichi Sankyo Revenue Growth Rate in Diabetic Neuropathy Drugs Business (2019-2024)
Figure 54. Astellas Pharma Revenue Growth Rate in Diabetic Neuropathy Drugs Business (2019-2024)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
